APOL1 and kidney disorder: Disclosure of APOL1 genetic risk results led to a greater decrease in SBP among those with high-risk APOL1 genotypes vs those with low-risk APOL1 genotypes and among those with high-risk APOL1 genotypes vs controls, as well as a significantly greater increase in urine kidney disease screening in all groups, especially among patients with high-risk APOL1 genotypes.